Inflammation biotech Evommune heads to NYSE with $150M IPO
Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO the inflammation biotech will use to fund a pair of clinical-stage candidates. The Palo…
Inflammation biotech Evommune prices IPO after MapLight’s $250M debut
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. The California biotech announced its IPO…
Inflammation biotech Evommune eyes IPO to fund further dermatitis trials
Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but Evommune has become the latest indicator that drug developers are…